clinical trial · NCT07088588
Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd·phase1·not yet recruiting·n = 105
Advanced Solid CancerMetastatic Solid TumorOvarian CancerBreast CancerBRCA MutationHRR DeficiencySYN608
brief summary
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN608 as monotherapy in adult patients with advanced solid tumors
started
Jul 31, 2025
primary completion
Jul 31, 2028
completion
Oct 31, 2028
last updated
Jul 28, 2025
detailed description
This study is a Phase I, open-label, multicentre study of SYN608 administered orally in patients with advanced solid tumors
official title
A First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYN608, a Poly ADP-ribose Glycohydrolase (PARG) Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol